… prior bicalutamide (except to prevent flare) or everolimus was allowed. Treatment included
oral bicalutamide 50 mg and oral everolimus … The primary endpoint was the prostate-specific …

… with bicalutamide and everolimus will result in improved efficacy compared to bicalutamide
… of the bicalutamide and everolimus combination in CRPC patients (pts) compared with …

… pathway is activated in castrate resistant prostate cancer (CRPC) while inhibition of this …
bicalutamide and the mTOR inhibitor everolimus in CRPC patients compared with bicalutamide …

… with bicalutamide and everolimus will result in improved efficacy compared to bicalutamide
… tolerability of the bicalutamide and everolimus combination in CRPC patients compared with …

… The majority of patients had received prior bicalutamide treatment; however, its use did not
… had previously been treated with bicalutamide, the addition of everolimus did not alleviate …

… widely implicated in many cancers, including prostate cancer [13]. … prostate cancers and in
up to 70% of advanced cancers, … RAD001 (everolimus) is an orally administered rapamycin …

… in men with prostate cancer. We sought … everolimus in men with high-risk prostate cancer
undergoing radical prostatectomy. Methods This is a randomized phase II study of everolimus …

… cell carcinoma [13], and was downregulated in our preclinical model of prostate cancer with
everolimus … We hypothesized that serum LDH levels, as a reflection in part of tumor mTOR …

… experience with everolimus for the treatment of prostate cancer has … everolimus alone or
in combination with bicalutamide, … results with everolimus therapy for prostate cancer have …

… A combination of bicalutamide and everolimus was evaluated in a clinical trial in mCRPC.
Only 2 of the 36 patients enrolled demonstrated a PSA response, and the median PFS was 8.7 …